FR2833266B1 - Nouveaux derives phosphonates, leur procede de preparation, leur utilisation comme modulateurs de l'activite des lymphocytes tgamma9 delta2 - Google Patents

Nouveaux derives phosphonates, leur procede de preparation, leur utilisation comme modulateurs de l'activite des lymphocytes tgamma9 delta2

Info

Publication number
FR2833266B1
FR2833266B1 FR0115971A FR0115971A FR2833266B1 FR 2833266 B1 FR2833266 B1 FR 2833266B1 FR 0115971 A FR0115971 A FR 0115971A FR 0115971 A FR0115971 A FR 0115971A FR 2833266 B1 FR2833266 B1 FR 2833266B1
Authority
FR
France
Prior art keywords
tgamma9
delta2
lymphocytes
modulators
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0115971A
Other languages
English (en)
French (fr)
Other versions
FR2833266A1 (fr
Inventor
Jean Louis Montero
Ibrahim Zgani
Chantal Menut
Valerie Gallois
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Laboratories Mayoly Spindler SAS
Universite de Montpellier
Original Assignee
Centre National de la Recherche Scientifique CNRS
Laboratories Mayoly Spindler SAS
Universite de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0115971A priority Critical patent/FR2833266B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Laboratories Mayoly Spindler SAS, Universite de Montpellier filed Critical Centre National de la Recherche Scientifique CNRS
Priority to JP2003551152A priority patent/JP2005511748A/ja
Priority to US10/498,313 priority patent/US20060241087A1/en
Priority to PCT/FR2002/004190 priority patent/WO2003050128A1/fr
Priority to AU2002366577A priority patent/AU2002366577A1/en
Priority to EP02804596A priority patent/EP1453840A1/fr
Publication of FR2833266A1 publication Critical patent/FR2833266A1/fr
Application granted granted Critical
Publication of FR2833266B1 publication Critical patent/FR2833266B1/fr
Priority to US12/656,049 priority patent/US8017596B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3826—Acyclic unsaturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3895—Pyrophosphonic acids; phosphonic acid anhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
FR0115971A 2001-12-11 2001-12-11 Nouveaux derives phosphonates, leur procede de preparation, leur utilisation comme modulateurs de l'activite des lymphocytes tgamma9 delta2 Expired - Fee Related FR2833266B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0115971A FR2833266B1 (fr) 2001-12-11 2001-12-11 Nouveaux derives phosphonates, leur procede de preparation, leur utilisation comme modulateurs de l'activite des lymphocytes tgamma9 delta2
US10/498,313 US20060241087A1 (en) 2001-12-11 2002-12-05 Phosphonates useful as modulators of t $g(g)9$g(d)2 lymphocyte activity
PCT/FR2002/004190 WO2003050128A1 (fr) 2001-12-11 2002-12-05 PHOSPHONATES UTILES COMME MODULATEURS DE L'ACTIVITE DES LYMPHOCYTES t-GAMMA-9-DELTA-2
AU2002366577A AU2002366577A1 (en) 2001-12-11 2002-12-05 Phosphonates useful as modulators of t $g(g)9$g(d)2 lymphocyte activity
JP2003551152A JP2005511748A (ja) 2001-12-11 2002-12-05 Ｔ−ガンマ−９−デルタ−２リンパ球の活性のモジュレーターとして有用なホスホネート
EP02804596A EP1453840A1 (fr) 2001-12-11 2002-12-05 Phosphonates utiles comme modulateurs de l'activite des lymphocytes t-gamma-9-delta-2
US12/656,049 US8017596B2 (en) 2001-12-11 2010-01-14 Phosphonates useful as modulators of T-γ-9-δ-2 activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0115971A FR2833266B1 (fr) 2001-12-11 2001-12-11 Nouveaux derives phosphonates, leur procede de preparation, leur utilisation comme modulateurs de l'activite des lymphocytes tgamma9 delta2

Publications (2)

Publication Number Publication Date
FR2833266A1 FR2833266A1 (fr) 2003-06-13
FR2833266B1 true FR2833266B1 (fr) 2004-10-22

Family

ID=8870319

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0115971A Expired - Fee Related FR2833266B1 (fr) 2001-12-11 2001-12-11 Nouveaux derives phosphonates, leur procede de preparation, leur utilisation comme modulateurs de l'activite des lymphocytes tgamma9 delta2

Country Status (6)

Country Link
US (2) US20060241087A1 (https=)
EP (1) EP1453840A1 (https=)
JP (1) JP2005511748A (https=)
AU (1) AU2002366577A1 (https=)
FR (1) FR2833266B1 (https=)
WO (1) WO2003050128A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212666D0 (en) * 2002-05-31 2002-07-10 Secr Defence Immunogenic sequences
WO2005054258A2 (en) * 2003-12-02 2005-06-16 Innate Pharma New class of gamma delta t cells activators and use thereof
EP1720567A2 (en) * 2004-02-10 2006-11-15 Innate Pharma Composition and method for the treatment of carcinoma
ATE419008T1 (de) * 2004-04-26 2009-01-15 Innate Pharma Adjuvante zusammensetzung und anwendungsverfahren dafür
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
CA2602223A1 (en) * 2005-03-22 2006-10-05 Christian Belmant New class of yo t cells activators and use thereof
US20090087456A1 (en) * 2005-09-07 2009-04-02 James Edward Eyles Adjuvanted vaccine
AU2006298677A1 (en) * 2005-10-06 2007-04-12 Innate Pharma Phosphoantigen salts of organic bases and methods for their crystallization
US8323664B2 (en) * 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
WO2008059052A1 (en) 2006-11-17 2008-05-22 Innate Pharma Improved methods of using phosphoantigen for the treatment of cancer
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
AU2018384632B2 (en) 2017-12-11 2021-10-21 The Procter & Gamble Company Oral care compositions comprising phosphonate and anionic group containing polymers
BR112020010126A2 (pt) * 2017-12-11 2020-10-13 The Procter & Gamble Company composições para tratamento bucal que compreendem fosfono-fosfato e polímeros contendo grupo aniônico
US11008411B2 (en) 2017-12-11 2021-05-18 The Procter & Gamble Company Phosphono-phosphate and anionic group containing polymers
WO2019118418A1 (en) 2017-12-11 2019-06-20 The Procter & Gamble Company Method of making phosphono-phosphate containing compounds
US11046798B2 (en) 2017-12-11 2021-06-29 The Procter & Gamble Company Phosphono-phosphate containing compounds and polymers
US11046817B2 (en) 2017-12-11 2021-06-29 The Procter & Gamble Company Compositions comprising multi-valent cations and phosphono-phosphate containing polymers
JP7065513B2 (ja) * 2018-06-29 2022-05-12 国立研究開発法人産業技術総合研究所 有機リン化合物
CA3114292A1 (en) 2018-09-27 2020-04-02 Phosphogam, Inc. Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR6914868D0 (pt) * 1969-01-23 1973-03-20 & Co Inc Merck Processos quimicos
ZA774977B (en) * 1976-09-06 1978-06-28 Sab Soc Etudes Applic Biolog Process for the preparation of 1,2-expoxypropyl-phosphonic acid derivatives
US4924024A (en) * 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
US5177239A (en) * 1989-07-18 1993-01-05 E. R. Squibb & Sons, Inc. Method for preparing a phosphonic acid ester
US5298655A (en) * 1991-09-27 1994-03-29 Merck & Co., Inc. Farnesyl pyrophosphate analogs
US5827838A (en) * 1992-10-06 1998-10-27 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno & Rijksuniversteit Te Leiden Method for the treatment of diseases related with protein isoprenylation
WO1994019357A1 (en) * 1993-02-23 1994-09-01 Merrell Dow Pharmaceuticals Inc. Farnesyl:protein transferase inhibitors as anticancer agents
US5463181A (en) * 1993-02-23 1995-10-31 Merrell Dow Pharmaceuticals Inc. Farnesyl: protein transferase inhibitors as anticancer agents
US5574025A (en) * 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
IT1276162B1 (it) * 1995-11-23 1997-10-27 Baldacci Lab Spa Geranilgeranil-derivati,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2782721B1 (fr) * 1998-09-01 2000-11-03 Inst Nat Sante Rech Med Nouveaux composes phosphohalohydrines, procede de fabrication et applications
FR2782722B1 (fr) * 1998-09-01 2001-01-12 Inst Nat Sante Rech Med Nouveaux composes phosphoepoxydes, procede de fabrication et applications
EP1153928B1 (en) * 1999-01-21 2005-12-21 Chugai Seiyaku Kabushiki Kaisha 2-methyl-3-butenyl-1-pyrophosphoric acid salts and agents for treating lymphocytes
FR2791981B1 (fr) * 1999-04-06 2001-07-20 Inst Nat Sante Rech Med Composes inhibant selectivement les lymphocytes tgamma9delta2, et leurs applications
EP1169996A1 (de) * 2000-07-06 2002-01-09 Ernst Mühlbauer Kg Phosphonsäuren enthaltendes Dentalmaterial
DE10201458A1 (de) 2001-04-11 2002-10-17 Adelbert Bacher Intermediate und Enzyme des Mevalonat-unabhängigen Isoprenoidbiosyntheseweg
WO2003009855A2 (de) * 2001-07-20 2003-02-06 Bioagency Ag Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen

Also Published As

Publication number Publication date
JP2005511748A (ja) 2005-04-28
US8017596B2 (en) 2011-09-13
FR2833266A1 (fr) 2003-06-13
US20060241087A1 (en) 2006-10-26
EP1453840A1 (fr) 2004-09-08
AU2002366577A1 (en) 2003-06-23
WO2003050128A1 (fr) 2003-06-19
US20100204184A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
FR2833266B1 (fr) Nouveaux derives phosphonates, leur procede de preparation, leur utilisation comme modulateurs de l'activite des lymphocytes tgamma9 delta2
MX199501B (es) Sintesis asimetrica de (-)6-cloro-4-ciclopropiletinil-4-trifluorometil-1,4-dihidro-2h-3,1-benzoxazin-2-ona
NO994077D0 (no) Fremgangsmåte for fremstilling av keramiske membraner
MA25223A1 (fr) Procede pour la preparation de 4-carboxy-amino-2-substitue-1,2,3,4 tetrahydroquinoleine
BG101893A (en) Nodulosporic acid derivatives
MA24182A1 (fr) Procede pour la preparation de 2,4-diaminopyrimidines substituees
ID28447A (id) Proses polimerisasi kontinu pembuatan poliamida-poliamida dari omega-aminonitril
EP1023250A4 (en) METHOD FOR PRODUCING 2,6-DIALKYLNAPHTHALINE
NO995551D0 (no) Fremgangsmåte for fremstilling av polymerer med nukleo-baser som sidegrupper
FR2833596B1 (fr) Procede de preparation de derives d'echinocandine
NO20003454D0 (no) FremgangsmÕte for fremstilling av (-)cis-3-hydroksy-1-metyl-4-
NO20000933D0 (no) Fremgangsmåte for fremstilling av polymer
FR2768725B1 (fr) Procede de preparation du 2-chloroprop-1-ene
EP1453470A4 (en) MODULATORS OF RHO C ACTIVITY
FR2807434B1 (fr) Nouveaux derives de la 1,2,3,4-tetrahydroisoquinoleine, leur procede de preparation et leur application comme fongicides
FR2771737B1 (fr) Procedes de production et d'epuration de 1,1-difluoroethane et produit ainsi obtenu
EP0971035A4 (en) METHOD FOR PRODUCING URIDINE DIPHOSPHATE-N-ACETYLGLUCOSAMINE (04/13/99)
FR2777006B1 (fr) Procede de preparation d'hydrogenosilanes par hydrogenolyse catalytique de polysilanes
FR2778917B1 (fr) Nouveaux derives d'histidine, procede de preparation et utilisations
FR2828207B1 (fr) Milieux de reaction pour l'activite thymidylate synthase de la thyx
EP1453813A4 (en) IMPROVED PURIFICATION OF 4,4- (5 -) - DI-t-BUTYL CYCLO HEXANO-18-KRONE-6
FR2808274B1 (fr) Procede de preparation des n, n'-carbonylbislactames
NO20005743D0 (no) Fremgangsmåte til fremstilling av 4,5-epoksymorfinan-6- oksyglukoronider
FR2785286B1 (fr) Nouveaux derives de la 2-[3-phenyl-2-propenyl]-1,2,3,4- tetrahydro-isoquinoleine, leur procede de preparation et leur application comme fongicides
FR2775973B1 (fr) Nouveaux derives d'histidine, procede de preparation et utilisations

Legal Events

Date Code Title Description
TQ Partial transmission of property
ST Notification of lapse

Effective date: 20140829